New hope for hard-to-treat cancers? drug combo enters human testing
NCT ID NCT04219254
First seen Nov 01, 2025 · Last updated May 12, 2026 · Updated 25 times
Summary
This early-stage trial tests a new antibody (BI-1206) combined with an existing immunotherapy (pembrolizumab) in adults with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if the combination is safe and can help control the disease. About 197 people will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR, ADULT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Centrul de Oncologie SF Nectarie SRL
RECRUITINGCraiova, Romania
Contact
-
Clinica Universidad de Navarra
RECRUITINGPamplona, Spain
Contact
-
HealthPartners Institute - Regions Cancer Care Center,
COMPLETEDSaint Paul, Minnesota, 55101, United States
-
Hospital Puerta de Hierro
NOT_YET_RECRUITINGMajadahonda, Spain
Contact
-
Hospital Universitari Dexeus
RECRUITINGBarcelona, Spain
Contact
-
Hospital Universitari Vall D´Hebron
RECRUITINGBarcelona, Spain
Contact
-
Hospital Virgen de la Macarena
RECRUITINGSeville, Spain
Contact
-
Institut Català d'Oncologia Hospital Duran i Reynals
RECRUITINGBarcelona, Spain
Contact
-
Institutul Oncologic "Prof. Dr. Ion Chiricuta"
RECRUITINGCluj-Napoca, Romania
Contact
-
Instytut Centrum Zdrowia Matki Polki
RECRUITINGLodz, Poland
Contact
-
Israel-Georgian Medical Research Clinic Helsicore
TERMINATEDTbilisi, Georgia
-
Jerarsi Clinic
RECRUITINGTbilisi, Georgia
Contact
-
Karolinska University Hospital, Solna
RECRUITINGStockholm, Sweden
Contact
-
LTD High Technology Hospital Med Center
RECRUITINGBatumi, Georgia
Contact
-
Lund University Hospital
RECRUITINGLund, Sweden
Contact
-
Maria Skłodowska-Curie National Institute of Oncology
TERMINATEDGliwice, Poland
-
Medical University of Silesia
NOT_YET_RECRUITINGKatowice, Poland
Contact
-
Medizinische Hochschule Hannover
NOT_YET_RECRUITINGHanover, Germany
Contact
-
NEXT Oncology
COMPLETEDSan Antonio, Texas, 78229, United States
-
Nationales Centrum für Tumorerkrankungen
NOT_YET_RECRUITINGHeidelberg, Germany
Contact
-
Oklahoma University , Stephenson Cancer Center
COMPLETEDOklahoma City, Oklahoma, 73104, United States
-
Sahlgrenska University Hospital
COMPLETEDGothenburg, Sweden
-
Sarah Cannon Research Institute
COMPLETEDDenver, Colorado, 80218, United States
-
University of California Los Angeles
NOT_YET_RECRUITINGLos Angeles, California, 90024, United States
Contact
-
Universität des Saarlandes
NOT_YET_RECRUITINGHomburg, Germany
Contact
Conditions
Explore the condition pages connected to this study.